Correlation between nail psoriasis severity index score with quality of life in nail psoriasis

Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease

Hard-to-treat areas in psoriasis vulgaris, i.e., the scalp, nails, genital area, palms, and soles, are less commonly diagnosed and treated. Our understanding of the complex etiopathogenesis and treatment of psoriasis vulgaris has advanced considerably in recent years. After performing an English literature search, the present article is a comprehensive review based on several relevant articles. The articles included met the following criteria: they mentioned the "hard-to-treat areas, special sites, difficult-to-treat areas" or the specific body location of psoriasis, and they reported the psoriasis prevalence and/or patients' quality of life. Despite the extensive information about psoriasis, there are still many limitations and challenges regarding the appropriate approach to psoriasis in these special locations. But emerging directions such as precise severity scores, new biomarkers for disease monitoring, and treatment decisions or forthcoming therapies represent solutions to improve the lives of those affected. Although they affect a small area, the impact on the quality of everyday life is significant, causing physical and mental disability. In this review, we try to highlight the need for more information about hard-to-treat areas, including their prevalence, a more rapid diagnosis, and a correct classification based on their real severity and their specific treatment before a significant impact on patients' quality of life occurs. By presenting these challenges, we hope to contribute to efforts at improving disease control.

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness

Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease's severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especially in the absence of significant body surface involvement. It is controversial whether the severity evaluation of patients with several affected areas (having at least one difficult-to-treat area) should be done differently from current methods. Scores used for special areas (PSSI, NAPSI and ESIF) allow an accurate assessment of disease severity in difficult-to-treat areas, but the issue of whether to integrate these scores into PASI, BSA or DLQI remains. The review's purpose resides in providing an overview of the main current issues in determining psoriasis severity in patients with psoriasis in difficult-to-treat areas and suggesting possible solutions for the optimal integration of the area assessment in current scores: severity can be either established according to the highest calculated score (PASI or PSSI or NAPSI or ESIF) or by adding a correction factor in the calculation of PASI for special areas.